Skip to Content
Merck

B5655

BCIP®/NBT

SIGMAFAST, alkaline phosphatase substrate, chromogenic, tablet

Synonym(s):

BCIP/NBT Substrate, BCIP®/NBT Alkaline Phosphatase Substrate

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
12352204
NACRES:
NA.83
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

SIGMAFAST BCIP®/NBT, tablet

form

tablet

Quality Level

solubility

water: 10 mL, clear, yellow

storage temp.

−20°C

Application

SIGMAFAST BCIP®/NBT has been used as a substrate
  • for the anti-mouse IgG conjugated alkaline phosphatase in immunoblotting
  • for alkaline phosphatase in the histochemical staining of primary osteoblasts
  • for alkaline phosphatase staining in bone marrow stromal cells

Preparation Note

Each tablet dissolved in 10 ml deionized water yields a ready-to-use buffered solution containing BCIP/NBT, pH 9.5.

Legal Information

BCIP is a registered trademark of Merck KGaA, Darmstadt, Germany
SIGMAFAST is a trademark of Sigma-Aldrich Co. LLC


Still not finding the right product?

Explore all of our products under SIGMAFAST BCIP®/NBT


Storage Class

11 - Combustible Solids



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Mitogen-activated protein kinase phosphatase 1 regulates bone mass, osteoblast gene expression, and responsiveness to parathyroid hormone
Mahalingam CD, et al.
The Journal of Endocrinology, 211(2), 145-156 (2011)
MicroRNA-183-5p increases with age in bone-derived extracellular vesicles, suppresses bone marrow stromal (stem) cell proliferation, and induces stem cell senescence
Davis C, et al.
Tissue Engineering: Part A, 23(21-22), 1231-1240 (2017)
R Gonzalez-Castro et al.
Inflammopharmacology, 26(3), 817-827 (2017-11-03)
The main amyloid-beta (Aβ) variants detected in the human brain are full-length Aβ1-40 and Aβ1-42 peptides; however, a significant proportion of AD brain Aβ consists also of N-terminal truncated/modified species. The majority of the previous immunotherapeutic strategies targeted the N-terminal